TendieTensor TendieTensor
You’re browsing as
Guest
Free Preview
Sign in/sign up to unlock all features.

News  ›  GlobeNewswire Inc.

Crinetics Announces First Patient Dosed in Phase 1/2 Trial Evaluating CRN09682 for the Treatment of Neuroendocrine Tumors and Other Somatostatin Receptor 2-Expressing Tumors

GlobeNewswire Inc. Logo GlobeNewswire Inc. By Crinetics Pharmaceuticals
Crinetics Announces First Patient Dosed in Phase 1/2 Trial Evaluating CRN09682 for the Treatment of Neuroendocrine Tumors and Other Somatostatin Receptor 2-Expressing Tumors

Crinetics Pharmaceuticals initiated a Phase 1/2 clinical trial for CRN09682, an investigational nonpeptide drug conjugate targeting somatostatin receptor type 2-positive neuroendocrine tumors, marking a significant milestone in developing a potentially more precise targeted therapy.

Insights
CRNX   positive

Company is advancing innovative drug development platform, initiating first-in-human trial for a novel therapeutic approach with potential to improve cancer treatment precision